| abstract |
The invention relates to peptides, proteins, nucleic acids and cells used in immunotherapy methods. In particular, the present invention relates to immunotherapy for cancer. The invention also relates to tumor-associated T-cell (CTL) peptide epitopes used alone or in combination with other tumor-associated peptides (stimulating anti-tumor immune response or in vitro stimulation of T cells and active pharmaceutical ingredients of vaccine complexes transferred into patients). Peptides that bind to major histocompatibility complex (MHC) molecules or peptides of this kind may also be targets for antibodies, soluble T cell receptors, and other binding molecules. |